108
Participants
Start Date
August 14, 2024
Primary Completion Date
November 14, 2025
Study Completion Date
November 14, 2025
Integrase inhibitor
Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC); 3) DTG 50mg+TDF 300mg/FTC 200mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks
Doravirine + tenofovir DF + lamivudine
Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to DOR/TDF/3TC 100/ 300/300 mg It will be prescribed one tablet every day during 48 weeks
RECRUITING
Hospital de infectología, Centro Médico Nacional La Raza, Mexico City
RECRUITING
Hospital de infectología, Centro Médico Nacional La Raza, Mexico City
Instituto Mexicano del Seguro Social
OTHER_GOV